studied SNPs in ABCB1 [9] . While the ABCB1-2677G>T/A gene polymorphism results in an amino-acid change from Ala to Ser/Thr at codon 893, the 1236C>T (Gly412Gly) and 3435C>T (Ile1144Ile) SNPs are synonymous [10] .
ABCB1-C3435T
The association between the ABCB1-C3435T gene polymorphism and treatment outcomes response in BC patients treated with neoadjuvant chemotherapy remains controversial. A meta-analysis published in 2012, including 7 studies (464 patients), found no influence between the ABCB1-C3435T gene polymorphism and treatment response in BC patients [11] . Recent studies have shown an association of the ABCB1-C3435T gene polymorphism with treatment response, although they differ in the positive effect of the T-allele on the response [12, 13] . In 148 BC patients treated with neoadjuvant chemotherapy, the ABCB1-C3435T T-allele carriers had a higher response (T-allele vs CC: 43.4% vs 23.8%, OR: 2.695; p = 0.02) [12] , whereas in 153 BC patients also treated with neoadjuvant chemotherapy, the C-allele was associated with higher response (C-allele vs TT: 71.2 vs 33.3%, p = 0.001) [13] .
A more recent meta-analysis including 8 studies (608 cases) found no association between the treatment response and the dominant model (CT + TT vs CC) of the ABCB1-C3435T gene polymorphism (OR: 1.13; 95% CI: 0.58-0.37; p = 0.71) [14] .
More recently, no association has been found either in a study of Kurdish BC patients (100 cases/200 controls) [15] or in 83 BC patients treated with chemotherapy plus trastuzumab [16] .
ABCB1-C1236T
T-allele carriers of the ABCB1-C1236T gene polymorphism showed worse response (T-allele vs CC: 58.3% vs 85%; OR non-responders/responders: 4.63; p = 0.021) in 100 BC patients treated with neoadjuvant chemotherapy [14] . These results were further confirmed in other studies (Agarwal: 2015fk, Tulsyan: 2014cy}. However, a meta-analysis conducted in 2013 by these authors, which included 3 studies (373 patients), found no association between the dominant model of the ABCB1-C1236T gene polymorphism, but a trend towards response to treatment (OR 1.77, 95% CI: 1.01-3.1; p = 0.05) [14] .
Recent studies not included in this meta-analysis have shown conflicting results. One study found an association between TT and CT genotypes and poor response to chemotherapy (OR: 0.35; 95 CI%: 0.13-1.90; p= 0.03) [17] in 100 Arabic BC patients treated with anthracycline-based chemotherapy. Another study performed in 83 Caucasian HER2-positive BC patients treated with chemotherapy plus trastuzumab showed no association, which was likely due to the smaller sample size [16] .
ABCB1-2677 G>T/A
The ABCB1-G2677T/A gene polymorphism was not associated with response to chemotherapy in 103 Korean MBC patients treated with adjuvant anthracycline plus paclitaxel [18] . This result was confirmed in a another Asian cohort of 153 BC patients treated with neoadjuvant anthracycline-based chemotherapy [13] and in an Indian study of 111 of BC patients treated with neoadjuvant/adjuvant chemotherapy [19] .
BC patients (61.5% HER2-positive) with GG + GT + GA genotypes of the ABCB1-G2677T/A gene polymorphism treated with the fluorouracil-doxorubicincyclophosphamide scheme, showed higher resistance to treatment than TT + TA patients. The multivariate analysis showed an OR of 3.19 (95% CI: 0.98 -10.39; p = 0.053) [20] .
The inconsistent conclusions in the association of the ABCB1 C1236T, C3435T and G2677T/A gene polymorphisms and the response to chemotherapy in BC patients led us to conduct a meta-analysis encompassing evidence from all published studies, in order to provide a more precise estimation of the association.
Study design
A meta-analysis was carried out.
Literature search strategy
A literature search was carried out using PubMed, Embase, Ovid and Scielo, and included all papers published until December 20th 2016, containing the keywords "ABCB1", "polymorphism", "breast", "cancer" and "response". In order to achieve a comprehensive literature, we also identified additional studies by screening reference lists of key studies or reviews. The literature retrieval was performed in duplication by two independent reviewers (AMP and MCG).
The inclusion criteria used for literature selection were: 1 Original papers.
2 Performed in humans.
3 Studies that explore the association between the three selected SNPS and chemotherapy response.
4 Papers with sufficient data to calculate odds ratio and 95% confidence interval. 
Statistical analysis
The strength of the association between the ABCB1 C3435T, C1236T and G2677T/A For the meta-analysis, the heterogeneity of the studies was determined using the Cochran Q chi-square test (p < 0.05 was considered as significant heterogeneity), alongside the degree of inconsistency presented as the I 2 index where I 2 of 0-25% = no heterogeneity; I 2 of 25-50% = moderate heterogeneity; I 2 of 50-75% = high heterogeneity and I 2 of 75-100% = extreme heterogeneity. The combined OR of all studies was calculated using the DerSimonian-Laird random effects model. The effect of the study was considered statistically significant if the confidence interval of the combined OR did not contain 1. The data of each analysis were graphically represented using funnel plots generated by the STATA program (Stata Software Package version 10 (StataCorp LP, College Station, Texas, USA)). The bias of publication was analysed by the Begg`s and Egger`s tests.
We analysed the overall effect of all studies for each of the ABCB1 gene polymorphisms, -C3435T, C1236T and G2677T/A, according to ethnicity, tumor type and response criteria. The software used for the meta-analysis was Metadisc [21] .
RESULTS

Study characteristics
A total of 44 studies were found with the keywords "ABCB1", "polymorphism", "breast", "cancer", "response".
We excluded 19 studies because they were written in Japanese, they included only pharmacokinetic data or because the analysis was performed in non-BC patients.
Seventeen studies were selected after eliminating all meta-analyses, one article whose drug in study was liposomal doxorubicin, one which considered survival as the dependent variable instead of response, and another which assessed only modifications in the expression of ABCB1. Of these 17, three further articles were discarded. Two had not used the RECIST/WHO criteria as a response measure and the third did not have the response data available for later use. Of the remaining articles, three had been developed by the same research group. The first, (Tulsyan et al. [27] ) was excluded because all data had been included in the study by Agarwal et al. [19] . This study [19] was kept for the general analysis as it was the most recently published article and included patients with various types of BC. The third article, by Chaturvedi et al. [14] , had also been published by the same research group. This study was used for the subgroup analysis which focused on the type of cancer, as its patients had locally advanced breast cancer (LABC) or metastatic breast cancer (MBC). The information from the final 12 studies included in analysis was extracted according to the gene polymorphism. This resulted in nine articles being included for the ABCB1- 
Meta-analysis
Nine articles were included for the ABCB1-C3435T gene polymorphism (770 patients) to calculate the combined OR (Table 1) . There was no association of this polymorphism with the response to chemotherapy in patients with BC in any of the models (dominant, recessive, codominant) ( Table 3) . Five studies, with a total of 566 patients were selected for analysis of the ABCB1-C1236T gene polymorphism. No association of this polymorphism with the response to chemotherapy was found in patients with BC, in any model (Table 4) . After the stratification by ethnicity, type of cancer and the criteria to measure the response according to the dominant, recessive or codominant models, no influence of these factors was found to be associated with the response to chemotherapy in BC patients for either the ABCB1 C3435T (Table 3 , Figures 1 and 2 ) or C1236T (Table 4 , Figure 3 ) gene polymorphisms. 
Test for heterogeneity
The heterogeneity of the studies used in each comparison of the ABCB1 C3435T and C1236T gene polymorphisms and response to chemotherapy, were diverse. These are detailed in Tables 3, 4 and 5 and include the degree of inconsistent data (I 2 index) and the Cochran Q chi-square test (heterogeneity: p<0.05). Heterogeneity was higher for the ABCB1-C1236T polymorphism models.
Publication bias
The Conversely, patients with TT genotype of ABCB1-C3435T showed a poorer response to neoadjuvant chemotherapy (33.3 vs. 71.2%, p = 0.001) [13] .
Our meta-analysis included 770 patients from nine studies confirmed the absence of the association between the response to chemotherapy and ABCB1-C3435T. These results are in agreement with the meta-analysis by Chen et al. [11] and Chaturvedi et al. [14] . by Chen et al., with the exception of the study by Ji et al. [13] , which was conducted in an Asian population, and data from their own study, focused on an Indian population [14] .
In our meta-analysis, the stratified analysis by types of cancer (primary + all types vs LABC + MBC), also showed no association with the response to chemotherapy in any genetic model of the ABCB1-C3435T polymorphism, with a high heterogeneity, especially in the subgroup of patients with LABC + MBC (I 2 = 46.0%; p = 0.099).
Other polymorphisms in ABCB1 have been explored as biomarkers of response. The T-allele of the ABCB1-C1236T gene polymorphism was associated with a poorer response (58.3% vs 85%, OR non-responders/responders : 4.63; p = 0.021) in 100 Indian BC patients treated with neoadjuvant chemotherapy, cyclophosphamide plus epirubicin or doxorubicin) [15, 19] . A similar trend was demonstrated by carriers of the T allele in a small cohort of 58 patients treated with neoadjuvant chemotherapy (57.4% vs. 81.8%, OR non-responders/responders : 3.33; p = 0.150), but without a statistically significant association, which is most likely due to the small sample size [27] . In our metaanalysis, the ABCB1-C1236T genetic polymorphism did not influence the response.
The different genetic models (dominant, recessive and co-dominant) of ABCB1-C1236T were not associated with the response to chemotherapy in the global metaanalysis. Stratification by ethnicity, cancer type and response measurement criteria did not provide information about the possible influence of these variables on the response to chemotherapy in BC patients. This data is in line with the meta-analysis including association between the ABCB1-C1236T gene polymorphism and response to chemotherapy in patients with BC, although a trend was shown (OR: 1.77; 95% CI:
1.01-3.10; p = 0.05) [14] . Our meta-analysis included all studies to date with a total of five (566 patients), increasing the accuracy of the study, and thus confirming the nonassociation of this polymorphism with the response to chemotherapy in BC patients.
The ABCB1-G2677T/A gene polymorphism was not associated with response to chemotherapy in 103 Korean MBC patients treated with adjuvant anthracycline plus paclitaxel [18] . This result was confirmed in a another Asian cohort of 153 BC patients treated with neoadjuvant anthracycline-based chemotherapy [13] and in an Indian study of 111 of BC patients treated with neoadjuvant/adjuvant chemotherapy [19] . Our meta-analysis included three studies (two in Asian population and one in an Indian population), and did not find an association between the ABCB1-G2677T/A, different genetic models and the response to chemotherapy.
These meta-analyses showed no association between ABCB1 polymorphisms and response to chemotherapy, despite some studies having shown contradictory results.
Possible causes of these differences may be the complexity of the phenomenon and gene-gene interactions [28] . Some intracellular alterations, as other unknown ABCB1 polymorphisms and errors in the posttranslational modification in the protein structure of P-glicoprotein, might balance the effect of these polymorphisms.
In our meta-analysis, one limitation is the high heterogeneity that has been found in the different comparisons, especially in relation to the ABCB1-C1236T gene polymorphism. This heterogeneity could be due to the fact that the analysis encompasses few studies, five in the global analysis, and fewer in the subgroup analyses.
The evidence provided by this work indicates that the ABCB1 C3435T, C1236T and G2677T/A gene polymorphisms are not associated with the response to chemotherapy in BC patients. No influence of ethnicity, cancer type and response criteria has been found. Subsequent studies focused on other polymorphisms could clarify the importance of this gene in the response to chemotherapy.
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